Replies to post #147920 on Biotech Values

[mcbio]

mcbio, my response to your post about PGNX is only about 3 weeks late. :)

Vin, better late than never my friend. ; )

There is no evidence or even hints that any issue arising from the chronic pain trial will impact Relistor usage in the AMI indication. Sub-Q Relistor sold $20 million in the first half of 2012, so it might reach $45 or maybe even $50 million for the year.

I just don't know that the existing approved indications for Relistor will be enough to move the dial for them even after the significantly dialed back market cap.

The calculus by SLXP must be; will oral Relistor boost AMI sales sufficiently to justify the $50 million milestone due to PGNX upon FDA approval of the Oral formulation. If they estimate say on the order of 50% boost in AMI sales, the answer could be yes, but who knows. I think we just have to wait until PGNX/SLXP finds out what the FDA wants and that should be known sometime in Sept.

Yeah, my biggest concern is what it's going to take to get the oral formulation approved. Just too much vagueness at this point for my tastes. I doubt I'll ever re-visit PGNX again but I sincerely hope it works out for you.